Researchers in Singapore have invented a kit for detecting whether a person has antibodies capable of neutralizing the coronavirus. This kit has become the first of its kind to receive emergency use authorization (EUA) from the USFDA. The kit, known as cPass, was co-developed by Duke-NUS Medical University and Singapore’s Agency for Science, Technology and Research's Diagnostics Development Hub. The cPass kit can detect circulating antibodies against SARS-CoV-2 by blocking the interaction between the receptor-binding domain (RBD) of the viral spike glycoprotein with the ACE2 cell surface receptor.
The kit also enables healthcare authorities to retrace the virus from its window period of infection. Another interesting fact about the kit is that it does not require highly specialized equipment or training to use, and the results can be obtained in just an hour. Since the kit is suitable…
